Literature DB >> 16697645

Disseminated spread of recurrent oligodendroglioma (WHO grade II).

Wai Hoe Ng1, Tchoyoson C C Lim, Kheng Kooi Tan.   

Abstract

Oligodendroglioma is a relatively uncommon primary brain tumour. The occurrence of metastatic dissemination of oligodendroglioma is rare and usually occurs in patients with anaplastic oligodendroglioma. The dissemination of WHO Grade II oligodendroglioma can occur and we report a patient with an initial diagnosis of a left temporal oligodendroglioma who presented with disseminated disease in the left temporal lobe, sellar region, medulla oblongata, both frontal lobes and ventricles more than 8 years later. Histology at dissemination showed anaplastic oligodendroglioma. Similar reports of metastatic dissemination of oligodendrogliomas reveal that the tumours may remain as WHO Grade II or may progress to anaplastic oligodendroglioma at metastasis. However, regardless of the histological grade at metastasis, the prognosis of metastatic oligodendroglioma is poor.

Entities:  

Mesh:

Year:  2006        PMID: 16697645     DOI: 10.1016/j.jocn.2005.05.020

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  4 in total

1.  Subependymal seeding of low-grade oligodendroglial neoplasms: a case series.

Authors:  Manal Nicolasjilwan; M Beatriz Lopes; James Larner; Max Wintermark; David Schiff
Journal:  J Neurooncol       Date:  2012-02-05       Impact factor: 4.130

2.  Interventricular low-grade oligodendroglioma with multiple parenchymal relapse.

Authors:  Ali Akhavan; Fariba Binesh; Afshin Rakhsha; Hossein Navabii
Journal:  BMJ Case Rep       Date:  2012-06-08

3.  Unusual intracranial spread of anaplastic oligodendroglioma.

Authors:  Ali Akhavan; Fariba Binesh; Hossein Navabii
Journal:  BMJ Case Rep       Date:  2012-08-13

4.  Extracranial metastasis of anaplastic oligoastrocytoma.

Authors:  Zhuang Kang; Shoubo Yang; Hongmei Zhang; Quan Zhou; Jianxin Chen; Yan Li; Xun Kang; Shan Li; Wenbin Li
Journal:  Cancer Biol Med       Date:  2018-08       Impact factor: 4.248

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.